Neurocrine-Soleno Deal Garners Wall Street Praise — Analyst Applauds Business Development Acumen

• The deal between Neurocrine and Soleno represents a total transaction equity value of $2.9 billion and will add Vykat XR tablet to Neurocrine’s existing portfolio.
• The transaction is not subject to any financing condition and is expected to close within 90 days, Neurocrine said. 
• Oppenheimer subsequently raised the firm's price target on Neurocrine to $220 from $192 and kept an ‘Outperform’ rating on the shares.

Neurocrine Biosciences Inc. (NBIX) said on Monday that it would acquire Soleno Therapeutics (SLNO) for $53 per share in cash, a move that was applauded by Wall Street.

The deal between Neurocrine and Soleno represents a total transaction equity value of $2.9 billion and will add Vykat XR tablet to Neurocrine’s existing portfolio including Ingrezza and Crenessity.

The transaction is not subject to any financing condition and is expected to close within 90 days, the company said.

Street Action

Oppenheimer subsequently raised the firm's price target on Neurocrine to $220 from $192 and kept an ‘Outperform’ rating on the shares following the announcement.

The firm sees Neurocrine's acquisition of Soleno Therapeutics (SLNO) as an ideal example of its industry-leading business development expertise considering the attractive $2.9 billion transaction value relative to the large and synergistic opportunity with Vykat XR for Prader-Willi Syndrome.

Vykat remains the first and only FDA-approved therapy for hyperphagia in Prader-Willi syndrome patients with $190 million in revenue in 2025, only three quarters into launch. Oppenheimer said that it further anticipates Neurocrine to leverage its medical and commercial infrastructure for its own portfolio including Crenessity and Ingrezza to accelerate sales.

How Did Retail Traders React?

On Stocktwits, retail sentiment around NBIX stock jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘extremely high’ levels.

Meanwhile, sentiment around SLNO stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the same time frame, while message volume rose from ‘high’ to ‘extremely high’ levels.

NBIX stock has gained 42% over the past 12 months while SLNO fell 25%. 

Read More: Tesla Vs. Ford: What Analysts Are Saying After Disappointing Q1 Deliveries

For updates and corrections, email newsroom[at]stocktwits[dot]com.